Global Autoimmune Monoclonal Antibodies Market – Industry Trends and Forecast to 2029

Autoimmune Monoclonal Antibodies Market Analysis and Size

The global autoimmune monoclonal antibodies market is expected to witness significant growth during the forecast period. Growing cases of severe arthritis & multiple sclerosis drives the autoimmune monoclonal antibodies market. Due to the increased family history of immune disease, the market has grown in autoimmune monoclonal antibodies. COVID-19 also had a major impact on the market growth.

Data Bridge Market Research analyses a growth rate in the global autoimmune monoclonal antibodies market in the forecast period 2022-2029. The expected CAGR of global autoimmune monoclonal antibodies market  is tend to be around 13% in the mentioned forecast period. The market was valued at USD 180 billion in 2021, and it would grow upto USD 478.52 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Autoimmune diseases are the condition in which body own immune system mistakenly attack normal body. In autoimmune diseases production of autoantibodies occurs which attack the healthy cell of body. Autoimmune monoclonal antibodies are the agents which acts as immunotherapy agent and protect the body healthy cell from the damage. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period.

Report Scope and Market Segmentation

Global Autoimmune Monoclonal Antibodies Market Dynamics

Drivers

• Increase in Arthritis Cases

Arthritis cases are becoming more prevalent with each passing year, especially osteoarthritis which has been affecting 15 million adults with an incidence ranging from 22% to 39% in India. Other common joint conditions affecting Indians are gout and rheumatoid arthritis. Osteoarthritis is more commonly observed in women and more prevalent with ageing. This boost the market growth.

• Rising Healthcare Awareness

Awareness among patients as well as healthcare providers about the incidence of autoimmune monoclonal antibodies is on the rise. Patients and doctors are now more actively participating in learning about the therapies available for treating these severe diseases. This is one of the most major drivers in the market.

Opportunities

• Patent Expiration Encourages New Launches

The patent expiration of old companies can create better opportunities for the new market players. Adopting combination therapies is a significant factor contributing to the growth of the monoclonal antibodies market. Further, R&D fundings are an add-on to the market.

• Rise in Cases of Multiple Sclerosis

The projected number of people with multiple sclerosis globally has increased to 2.8 million in the year 2020. The countries with the maximum incidence of multiple sclerosis include Canada, Denmark, Sweden and San Marino. Thus, it these high number of cases creates more opportunity to the market growth.

Restraints/Challenges

• Lack of Skilled Professionals

Lack of trained professionals who are unaware of the knowledge of the treatment methods for this disease could curb the growth of the global autoimmune monoclonal antibodies market over a forecast period.

• Increasing Cost Of Treatments

The huge expenditure required for the treatment methods surely hamper the market growth. Many of the treatments involved in this disease require high cost and thus at times gets difficult for many people, especially the ones in the rural areas. Thus, this can act as a major hindrance factor for the market.

This global autoimmune monoclonal antibodies market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global autoimmune monoclonal antibodies market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Autoimmune Monoclonal Antibodies Market Scope

The global autoimmune monoclonal antibodies market is segmented on the basis of indication, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Indication

• Rheumatoid Arthritis
• Systemic Lupus Erythematosus
• Multiple Sclerosis
• Organ Transplant Rejection
• Myasthenia Gravis
• Others

Route of Administration

• Parenteral
• Others

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Autoimmune Monoclonal Antibodies Market Regional Analysis/Insights

The global autoimmune monoclonal antibodies market is analysed and market size insights and trends are provided by indication, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global autoimmune monoclonal antibodies market  report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific is expected to have the highest market growth due to increased prevalence of arthritis and related disorders and number of generic drugs.

North America dominates the market due to latest technology development and presences of variety of innovative drug molecule to enhance the treatment procedure.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Autoimmune Monoclonal Antibodies Market Share Analysis

The global autoimmune monoclonal antibodies market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global autoimmune monoclonal antibodies market.

Key players operating in the global autoimmune monoclonal antibodies market include:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GSK plc (U.K.)
• Novartis AG (Switzerland)
• Bayer AG (Germany)
• Lilly (U.S.)
• Merck & Co., Inc. (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• Lupin (India)
• Fresenius Kabi AG (Germany)
• Akorn Incorporated (U.S.)
• Teva Pharmaceutical Industries Ltd (Israel)

SKU-53944